From Grok: No, there are no FDA accelerated approvals

New Post Public Reply Private Reply Replies (2) Message Board
skezan Jake2212 #160035
630
From Grok:
No, there are no FDA accelerated approvals granted based solely on a Phase 1 trial.
The FDA's Accelerated Approval pathway (established in 1992 and updated over time) allows earlier approval for drugs treating serious or life-threatening conditions with unmet needs, using surrogate endpoints (e.g., tumor response rates in oncology) or intermediate clinical endpoints reasonably likely to predict clinical benefit. However, this requires data from an "adequate and well-controlled" study—typically a pivotal trial showing meaningful effect on such an endpoint.
Key Reasons Why Pure Phase 1-Only Accelerated Approvals Do Not Occur
Phase 1 focus: These trials primarily assess safety, dosing, pharmacokinetics, and initial tolerability in small groups (often 20–100 participants, sometimes healthy volunteers or patients in oncology). They are not designed or powered to provide robust efficacy data on surrogate endpoints sufficient for approval.
Pivotal evidence requirement: Accelerated approvals rely on evidence from single-arm or randomized trials demonstrating durable responses or other surrogates. Historical examples (e.g., many oncology drugs) use Phase 2 data, expanded Phase 1/2 cohorts, or early Phase 3 signals—not standalone Phase 1.
Analyses of approvals: Studies of accelerated approvals (e.g., 2015–2022 data) show that ~22% of pre-approval pivotal trials supporting accelerated approvals were Phase 1 trials. However, these were not "Phase 1 only"—they involved Phase 1 expansions or combined Phase 1/2 designs where the efficacy signal came from larger patient cohorts treated at the recommended dose, often functioning as de facto pivotal data with response rates and duration of response. Even in those cases, the approval was not based exclusively on initial dose-escalation Phase 1 portions.
FDA guidance and practice: Recent oncology guidance prefers randomized controlled trials for accelerated approval, and single-arm trials (common historically) still need substantial, interpretable efficacy signals beyond basic safety. No official FDA documentation, approval lists, or analyses describe any case of accelerated approval from Phase 1 safety/dosing data alone without efficacy demonstration.
Closest Scenarios (But Not "Phase 1 Only"
Some modern accelerated approvals in oncology (e.g., certain bispecifics or targeted therapies) have included data from Phase 1 trials with strong, durable response rates in expansion cohorts.
Recent policy shifts (as of 2026) emphasize one high-quality pivotal trial (which could be early-phase in rare diseases) plus confirmatory evidence, but this still requires efficacy demonstration—not pure Phase 1 safety data.
Examples like Gleevec historically used Phase 2 data; more recent cases blend phases but never rely solely on standard Phase 1.
In summary, while accelerated approval can draw from early-phase data (especially in oncology or rare diseases with compelling signals), no drug has received accelerated approval based exclusively on a traditional Phase 1 trial without efficacy-supporting data from expanded cohorts or later phases. All accelerated approvals require evidence reasonably likely to predict benefit, which Phase 1 alone does not provide. For the most current list of accelerated approvals, check the FDA's Accelerated Approval Program page or Drugs@FDA database. If you're asking about a specific drug, therapeutic area, or recent example, provide details for more targeted info!

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Worker Pullback Is a Cost Problem Employers Ignore

Updated Category News Views 86

Somewhere between a job description and an unpaid favor, a lot of corporate productivity appears to be quietly leaking out. MyPerfectResume’s July 2026 survey of 1,000 U.S. workers says 78% have intentionally done only the minimum needed to keep their jobs at least once. That is not a cute workplace-culture headline. It is a warning flare about discretionary...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
YYForce Security Win Adds Recurring Singapore Revenue Base

Updated Category News Views 160

A retail-property security mandate rarely makes anyone pound the table, and frankly it should not. Still, YYForce has landed a tangible two-year contract in Singapore worth roughly S$831,120, with subsidiary Uniforce Security Services set to begin work on December 1, 2026. For NASDAQ:YFOR investors, this is the kind of small, operationally real win that deserves a sober...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 55

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 111

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 72

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 88

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 79

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 61

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading

Top 5 Most Recently Viewed Articles

Examining the Latest Trends in Beyond Meat's Short Selling

Updated Category News Views 624

Understanding Beyond Meat's Short Interest Dynamics Beyond Meat (NASDAQ: BYND) has seen an increase in its short percent of float, now at 4.44% higher than the last report. Currently, 24.77 million shares have been sold short, constituting a substantial 39.78% of the total shares available for trading. Given the current trading volume, it would take approximately 10.11...

Continue Reading
Vestis Corporation Faces Class Action Amid Financial Woes

Updated Category News Views 231

Vestis Corporation's Class Action Lawsuit Announcement Pomerantz LLP has formally announced a class action lawsuit targeting Vestis Corporation (NASDAQ: VSTS). This lawsuit stems from allegations of securities fraud and other improper business practices potentially committed by the Company and its executives. Investors who have incurred losses from their investments in...

Continue Reading
Join Ring Energy's Insightful Fireside Chat on Industry Trends

Updated Category News Views 192

Exciting Participation of Ring Energy in Upcoming Fireside Chat Ring Energy, Inc. (NYSE American: REI) has announced its upcoming participation in a noteworthy fireside chat hosted by Water Tower Research. Insights from Industry Leaders This engaging discussion is scheduled to take place at 10:00 AM Central Time, featuring Paul McKinney, the Chairman and Chief Executive...

Continue Reading
SEGG Media's Exciting Leap into NBA Advertising Strategy

Updated Category News Views 191

SEGG Media Strengthens Presence in the NBA SEGG Media Corporation has made significant strides in expanding its brand influence within the U.S. sports landscape. The company, which is the parent organization of Sports.com, has recently announced a strategic initiative to feature full-page advertisements in yearbooks for seven premier NBA teams during the upcoming season....

Continue Reading
Federal Home Loan Bank of Atlanta Reports Q3 2024 Financial Overview

Updated Category News Views 95

Financial Highlights of Federal Home Loan Bank of Atlanta The Federal Home Loan Bank of Atlanta has recently shared its preliminary financial highlights for the third quarter of 2024, showcasing important metrics and performance results. The Bank's quarterly outcomes signal core functionalities and adjustments aimed at sustaining a strong financial foundation. Key...

Continue Reading